This inventor holds 2 USPTO granted patents. Top assignee: Eutilex Co., Ltd.. Active years: 2020-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2021
Title: Seunghyun Lee: Innovator in Cancer Treatment
Introduction
Seunghyun Lee is a prominent inventor based in Gwangmyeong-si, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and development of novel antibodies.
Latest Patents
Seunghyun Lee holds 2 patents, including his latest work on IFN-gamma-inducible regulatory T cell convertible anti-cancer (IRTCA) antibodies. These antibodies and their antigen-binding fragments are designed to bind to an activation-inducible TNFR (AITR) polypeptide. The patents detail various in vitro and in vivo methods and compositions related to IRTCA antibodies. These methods include altering cytokine secretion from T cells and providing prevention and therapeutic treatment of cancer using IRTCA antibodies or their fragments.
Career Highlights
Seunghyun Lee is associated with Eutilex Co., Ltd., where he continues to advance his research in cancer therapies. His work is pivotal in developing innovative solutions that could potentially change the landscape of cancer treatment.
Collaborations
He collaborates with notable colleagues, including Byoung S Kwon and Seoung-Joo Lee, to further enhance the impact of his research and innovations.
Conclusion
Seunghyun Lee's contributions to cancer treatment through his patents and collaborative efforts highlight his role as a key innovator in the field. His work promises to pave the way for new therapeutic options in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile